STOCK TITAN

[D] Bridgewater Bancshares, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
D
Rhea-AI Filing Summary

BioCardia, Inc. (Nasdaq: BCDA) filed a Rule 424(b)(5) prospectus supplement on July 8, 2025 to enlarge its ongoing at-the-market (ATM) equity program with H.C. Wainwright & Co. The supplement authorizes the sale of up to $3.63 million in additional common shares, over and above the roughly $3.1 million already issued under the existing Sales Agreement.

The company’s non-affiliate float is valued at approximately $12.8 million (4,487,631 shares at $2.85 per share as of May 9, 2025). Pursuant to Form S-3 General Instruction I.B.6, BioCardia may not sell more than one-third of this float within any 12-month period while its market value remains below $75 million; the new limit therefore aligns with the regulatory cap. To date, ATM sales during the current 12-month window total about $0.6 million, leaving the full $3.63 million capacity available.

The offering will be made “at the market,” meaning shares may be issued intermittently at prevailing prices, last reported at $2.10 per share on July 7, 2025. Proceeds are expected to support general corporate purposes. Investors should consider dilution risk and the previously disclosed risk factors incorporated from earlier prospectus filings.

BioCardia, Inc. (Nasdaq: BCDA) ha depositato un supplemento al prospetto secondo la Regola 424(b)(5) l'8 luglio 2025 per ampliare il suo programma di equity "at-the-market" (ATM) in corso con H.C. Wainwright & Co. Il supplemento autorizza la vendita di ulteriori azioni ordinarie per un valore massimo di 3,63 milioni di dollari, oltre ai circa 3,1 milioni di dollari già emessi secondo l'Accordo di Vendita esistente.

Il flottante non affiliato della società è valutato circa 12,8 milioni di dollari (4.487.631 azioni a 2,85 dollari per azione al 9 maggio 2025). In base alle Istruzioni Generali I.B.6 del Modulo S-3, BioCardia non può vendere più di un terzo di questo flottante in un periodo di 12 mesi mentre il valore di mercato rimane sotto i 75 milioni di dollari; il nuovo limite quindi rispetta il tetto normativo. Finora, le vendite ATM nel periodo di 12 mesi corrente ammontano a circa 0,6 milioni di dollari, lasciando disponibile l'intera capacità di 3,63 milioni di dollari.

L'offerta sarà effettuata "at the market", ovvero le azioni potranno essere emesse in modo intermittente ai prezzi correnti, ultimi riportati a 2,10 dollari per azione il 7 luglio 2025. I proventi sono destinati a sostenere scopi aziendali generali. Gli investitori devono considerare il rischio di diluizione e i fattori di rischio già divulgati nei prospetti precedenti.

BioCardia, Inc. (Nasdaq: BCDA) presentó un suplemento al prospecto bajo la Regla 424(b)(5) el 8 de julio de 2025 para ampliar su programa continuo de acciones "at-the-market" (ATM) con H.C. Wainwright & Co. El suplemento autoriza la venta de hasta 3,63 millones de dólares adicionales en acciones comunes, además de los aproximadamente 3,1 millones de dólares ya emitidos bajo el Acuerdo de Venta existente.

El flotante no afiliado de la compañía está valorado en aproximadamente 12,8 millones de dólares (4.487.631 acciones a 2,85 dólares por acción al 9 de mayo de 2025). Conforme a la Instrucción General I.B.6 del Formulario S-3, BioCardia no puede vender más de un tercio de este flotante dentro de un periodo de 12 meses mientras su valor de mercado permanezca por debajo de 75 millones de dólares; por lo tanto, el nuevo límite se ajusta al tope regulatorio. Hasta la fecha, las ventas ATM durante el periodo actual de 12 meses suman aproximadamente 0,6 millones de dólares, dejando disponible toda la capacidad de 3,63 millones de dólares.

La oferta se realizará "at the market", lo que significa que las acciones pueden emitirse de forma intermitente a los precios vigentes, reportados por última vez en 2,10 dólares por acción el 7 de julio de 2025. Se espera que los ingresos apoyen propósitos corporativos generales. Los inversionistas deben considerar el riesgo de dilución y los factores de riesgo previamente divulgados en prospectos anteriores.

BioCardia, Inc. (나스닥: BCDA)는 2025년 7월 8일 Rule 424(b)(5)에 따른 보충 설명서를 제출하여 H.C. Wainwright & Co.와 함께 진행 중인 시장가 매출(ATM) 주식 프로그램을 확대했습니다. 이 보충 설명서는 기존 판매 계약에 따라 이미 발행된 약 310만 달러를 초과하여 최대 363만 달러 상당의 추가 보통주 판매를 승인합니다.

회사의 비계열 유통 주식 가치는 약 1280만 달러(2025년 5월 9일 기준 주당 2.85달러, 4,487,631주)로 평가됩니다. Form S-3 일반 지침 I.B.6에 따라, BioCardia는 시가총액이 7500만 달러 미만인 동안 12개월 내에 이 유통 주식의 3분의 1 이상을 판매할 수 없으며, 따라서 이번 신규 한도는 규제 상한선과 일치합니다. 현재까지 12개월 기간 내 ATM 판매액은 약 60만 달러로, 전체 363만 달러 한도가 남아 있습니다.

이번 공모는 "시장가" 방식으로 진행되며, 이는 주식이 간헐적으로 현재 가격에 발행될 수 있음을 의미합니다. 2025년 7월 7일 마지막 보고 가격은 주당 2.10달러입니다. 수익금은 일반 기업 목적에 사용될 예정입니다. 투자자들은 희석 위험과 이전에 공시된 위험 요소들을 고려해야 합니다.

BioCardia, Inc. (Nasdaq : BCDA) a déposé un supplément au prospectus conformément à la règle 424(b)(5) le 8 juillet 2025 afin d'élargir son programme d'actions "at-the-market" (ATM) en cours avec H.C. Wainwright & Co. Ce supplément autorise la vente de jusqu'à 3,63 millions de dollars d'actions ordinaires supplémentaires, en plus des environ 3,1 millions de dollars déjà émises dans le cadre de l'accord de vente existant.

Le flottant non affilié de la société est estimé à environ 12,8 millions de dollars (4 487 631 actions à 2,85 dollars par action au 9 mai 2025). Conformément à l'instruction générale I.B.6 du formulaire S-3, BioCardia ne peut pas vendre plus d'un tiers de ce flottant sur une période de 12 mois tant que sa valeur marchande reste inférieure à 75 millions de dollars ; la nouvelle limite est donc conforme au plafond réglementaire. À ce jour, les ventes ATM au cours des 12 derniers mois s'élèvent à environ 0,6 million de dollars, laissant toute la capacité de 3,63 millions de dollars disponible.

L'offre sera réalisée "at the market", ce qui signifie que les actions peuvent être émises de manière intermittente aux prix en vigueur, dernier prix rapporté à 2,10 dollars par action le 7 juillet 2025. Les produits devraient soutenir les besoins généraux de l'entreprise. Les investisseurs doivent prendre en compte le risque de dilution ainsi que les facteurs de risque précédemment divulgués dans les prospectus antérieurs.

BioCardia, Inc. (Nasdaq: BCDA) reichte am 8. Juli 2025 einen Prospektergänzungsbericht gemäß Rule 424(b)(5) ein, um sein laufendes "at-the-market" (ATM) Eigenkapitalprogramm mit H.C. Wainwright & Co. zu erweitern. Der Ergänzungsbericht autorisiert den Verkauf von bis zu 3,63 Millionen US-Dollar zusätzlichen Stammaktien, zusätzlich zu den bereits unter dem bestehenden Verkaufsvertrag ausgegebenen rund 3,1 Millionen US-Dollar.

Der nicht verbundene Streubesitz des Unternehmens wird auf etwa 12,8 Millionen US-Dollar geschätzt (4.487.631 Aktien zu je 2,85 US-Dollar am 9. Mai 2025). Gemäß der Allgemeinen Anweisung I.B.6 des Formulars S-3 darf BioCardia innerhalb eines Zeitraums von 12 Monaten nicht mehr als ein Drittel dieses Streubesitzes verkaufen, solange der Marktwert unter 75 Millionen US-Dollar liegt; die neue Grenze entspricht somit dem regulatorischen Limit. Bislang belaufen sich die ATM-Verkäufe im aktuellen 12-Monats-Zeitraum auf etwa 0,6 Millionen US-Dollar, sodass die volle Kapazität von 3,63 Millionen US-Dollar noch verfügbar ist.

Das Angebot erfolgt "at the market", das heißt, Aktien können zeitweise zu den jeweils aktuellen Preisen ausgegeben werden, zuletzt gemeldet zu 2,10 US-Dollar pro Aktie am 7. Juli 2025. Die Erlöse sollen allgemeinen Unternehmenszwecken dienen. Investoren sollten das Verwässerungsrisiko sowie die bereits offengelegten Risikofaktoren aus früheren Prospekten berücksichtigen.

Positive
  • Enhanced liquidity: Ability to raise up to $3.63 million without a separate follow-on offering.
  • Regulatory alignment: Maintains compliance with Form S-3 I.B.6 limits, avoiding registration constraints.
Negative
  • Dilution risk: Additional shares issued into the open market may pressure the stock price.
  • Small float sensitivity: With a $12.8 million public float, even modest issuance volumes can materially impact per-share metrics.

Insights

TL;DR – Neutral: modest ATM increase supplies liquidity but adds dilution pressure.

The supplement merely refreshes BioCardia’s ATM shelf to the maximum allowed one-third-of-float threshold. Management has tapped only $0.6 million in the last year, signalling measured use so far. With a market cap under $20 million, every incremental issuance is dilutive, yet raising up to $3.6 million could extend cash runway by several quarters without a large, deeply discounted placement. Unless utilisation accelerates materially, the impact on share price should be limited to routine ATM overhang, keeping my overall rating neutral.

TL;DR – Provides flexible funding; regulatory compliance intact; limited strategic impact.

BioCardia remains within Form S-3 I.B.6 parameters, demonstrating prudent shelf-usage governance. The updated cap equal to one-third of float (~$3.63 million) preserves financing optionality without renegotiating the Sales Agreement. H.C. Wainwright’s role as agent ensures execution efficiency but historically carries higher fees. For a micro-cap with constrained capital access, an ATM is cost-effective compared with PIPEs or convertible debt. Still, the modest size signals no immediate large-scale clinical or M&A spending. Investors should monitor issuance pace and any acceleration that could compress the float further.

BioCardia, Inc. (Nasdaq: BCDA) ha depositato un supplemento al prospetto secondo la Regola 424(b)(5) l'8 luglio 2025 per ampliare il suo programma di equity "at-the-market" (ATM) in corso con H.C. Wainwright & Co. Il supplemento autorizza la vendita di ulteriori azioni ordinarie per un valore massimo di 3,63 milioni di dollari, oltre ai circa 3,1 milioni di dollari già emessi secondo l'Accordo di Vendita esistente.

Il flottante non affiliato della società è valutato circa 12,8 milioni di dollari (4.487.631 azioni a 2,85 dollari per azione al 9 maggio 2025). In base alle Istruzioni Generali I.B.6 del Modulo S-3, BioCardia non può vendere più di un terzo di questo flottante in un periodo di 12 mesi mentre il valore di mercato rimane sotto i 75 milioni di dollari; il nuovo limite quindi rispetta il tetto normativo. Finora, le vendite ATM nel periodo di 12 mesi corrente ammontano a circa 0,6 milioni di dollari, lasciando disponibile l'intera capacità di 3,63 milioni di dollari.

L'offerta sarà effettuata "at the market", ovvero le azioni potranno essere emesse in modo intermittente ai prezzi correnti, ultimi riportati a 2,10 dollari per azione il 7 luglio 2025. I proventi sono destinati a sostenere scopi aziendali generali. Gli investitori devono considerare il rischio di diluizione e i fattori di rischio già divulgati nei prospetti precedenti.

BioCardia, Inc. (Nasdaq: BCDA) presentó un suplemento al prospecto bajo la Regla 424(b)(5) el 8 de julio de 2025 para ampliar su programa continuo de acciones "at-the-market" (ATM) con H.C. Wainwright & Co. El suplemento autoriza la venta de hasta 3,63 millones de dólares adicionales en acciones comunes, además de los aproximadamente 3,1 millones de dólares ya emitidos bajo el Acuerdo de Venta existente.

El flotante no afiliado de la compañía está valorado en aproximadamente 12,8 millones de dólares (4.487.631 acciones a 2,85 dólares por acción al 9 de mayo de 2025). Conforme a la Instrucción General I.B.6 del Formulario S-3, BioCardia no puede vender más de un tercio de este flotante dentro de un periodo de 12 meses mientras su valor de mercado permanezca por debajo de 75 millones de dólares; por lo tanto, el nuevo límite se ajusta al tope regulatorio. Hasta la fecha, las ventas ATM durante el periodo actual de 12 meses suman aproximadamente 0,6 millones de dólares, dejando disponible toda la capacidad de 3,63 millones de dólares.

La oferta se realizará "at the market", lo que significa que las acciones pueden emitirse de forma intermitente a los precios vigentes, reportados por última vez en 2,10 dólares por acción el 7 de julio de 2025. Se espera que los ingresos apoyen propósitos corporativos generales. Los inversionistas deben considerar el riesgo de dilución y los factores de riesgo previamente divulgados en prospectos anteriores.

BioCardia, Inc. (나스닥: BCDA)는 2025년 7월 8일 Rule 424(b)(5)에 따른 보충 설명서를 제출하여 H.C. Wainwright & Co.와 함께 진행 중인 시장가 매출(ATM) 주식 프로그램을 확대했습니다. 이 보충 설명서는 기존 판매 계약에 따라 이미 발행된 약 310만 달러를 초과하여 최대 363만 달러 상당의 추가 보통주 판매를 승인합니다.

회사의 비계열 유통 주식 가치는 약 1280만 달러(2025년 5월 9일 기준 주당 2.85달러, 4,487,631주)로 평가됩니다. Form S-3 일반 지침 I.B.6에 따라, BioCardia는 시가총액이 7500만 달러 미만인 동안 12개월 내에 이 유통 주식의 3분의 1 이상을 판매할 수 없으며, 따라서 이번 신규 한도는 규제 상한선과 일치합니다. 현재까지 12개월 기간 내 ATM 판매액은 약 60만 달러로, 전체 363만 달러 한도가 남아 있습니다.

이번 공모는 "시장가" 방식으로 진행되며, 이는 주식이 간헐적으로 현재 가격에 발행될 수 있음을 의미합니다. 2025년 7월 7일 마지막 보고 가격은 주당 2.10달러입니다. 수익금은 일반 기업 목적에 사용될 예정입니다. 투자자들은 희석 위험과 이전에 공시된 위험 요소들을 고려해야 합니다.

BioCardia, Inc. (Nasdaq : BCDA) a déposé un supplément au prospectus conformément à la règle 424(b)(5) le 8 juillet 2025 afin d'élargir son programme d'actions "at-the-market" (ATM) en cours avec H.C. Wainwright & Co. Ce supplément autorise la vente de jusqu'à 3,63 millions de dollars d'actions ordinaires supplémentaires, en plus des environ 3,1 millions de dollars déjà émises dans le cadre de l'accord de vente existant.

Le flottant non affilié de la société est estimé à environ 12,8 millions de dollars (4 487 631 actions à 2,85 dollars par action au 9 mai 2025). Conformément à l'instruction générale I.B.6 du formulaire S-3, BioCardia ne peut pas vendre plus d'un tiers de ce flottant sur une période de 12 mois tant que sa valeur marchande reste inférieure à 75 millions de dollars ; la nouvelle limite est donc conforme au plafond réglementaire. À ce jour, les ventes ATM au cours des 12 derniers mois s'élèvent à environ 0,6 million de dollars, laissant toute la capacité de 3,63 millions de dollars disponible.

L'offre sera réalisée "at the market", ce qui signifie que les actions peuvent être émises de manière intermittente aux prix en vigueur, dernier prix rapporté à 2,10 dollars par action le 7 juillet 2025. Les produits devraient soutenir les besoins généraux de l'entreprise. Les investisseurs doivent prendre en compte le risque de dilution ainsi que les facteurs de risque précédemment divulgués dans les prospectus antérieurs.

BioCardia, Inc. (Nasdaq: BCDA) reichte am 8. Juli 2025 einen Prospektergänzungsbericht gemäß Rule 424(b)(5) ein, um sein laufendes "at-the-market" (ATM) Eigenkapitalprogramm mit H.C. Wainwright & Co. zu erweitern. Der Ergänzungsbericht autorisiert den Verkauf von bis zu 3,63 Millionen US-Dollar zusätzlichen Stammaktien, zusätzlich zu den bereits unter dem bestehenden Verkaufsvertrag ausgegebenen rund 3,1 Millionen US-Dollar.

Der nicht verbundene Streubesitz des Unternehmens wird auf etwa 12,8 Millionen US-Dollar geschätzt (4.487.631 Aktien zu je 2,85 US-Dollar am 9. Mai 2025). Gemäß der Allgemeinen Anweisung I.B.6 des Formulars S-3 darf BioCardia innerhalb eines Zeitraums von 12 Monaten nicht mehr als ein Drittel dieses Streubesitzes verkaufen, solange der Marktwert unter 75 Millionen US-Dollar liegt; die neue Grenze entspricht somit dem regulatorischen Limit. Bislang belaufen sich die ATM-Verkäufe im aktuellen 12-Monats-Zeitraum auf etwa 0,6 Millionen US-Dollar, sodass die volle Kapazität von 3,63 Millionen US-Dollar noch verfügbar ist.

Das Angebot erfolgt "at the market", das heißt, Aktien können zeitweise zu den jeweils aktuellen Preisen ausgegeben werden, zuletzt gemeldet zu 2,10 US-Dollar pro Aktie am 7. Juli 2025. Die Erlöse sollen allgemeinen Unternehmenszwecken dienen. Investoren sollten das Verwässerungsrisiko sowie die bereits offengelegten Risikofaktoren aus früheren Prospekten berücksichtigen.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL
OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number) Previous Names
X None
Entity Type
0001341317
X Corporation
Limited Partnership
Limited Liability Company
General Partnership
Business Trust
Other (Specify)

Name of Issuer
Bridgewater Bancshares Inc
Jurisdiction of Incorporation/Organization
MINNESOTA
Year of Incorporation/Organization
X Over Five Years Ago
Within Last Five Years (Specify Year)
Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Bridgewater Bancshares Inc
Street Address 1 Street Address 2
4450 EXCELSIOR BLVD. SUITE 100
City State/Province/Country ZIP/PostalCode Phone Number of Issuer
ST. LOUIS PARK MINNESOTA 55416 952-893-6868

3. Related Persons

Last Name First Name Middle Name
Baack Jerry
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Chairman and CEO
Last Name First Name Middle Name
Chybowski Joe
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

President and CFO
Last Name First Name Middle Name
Crocker Mary Jayne
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Executive VP and Chief Strategy Officer
Last Name First Name Middle Name
Place Nick
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Banking Officer
Last Name First Name Middle Name
Salazar Lisa
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Operating Officer
Last Name First Name Middle Name
Shellberg Jeff
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Executive VP and Chief Credit Officer
Last Name First Name Middle Name
Brezonik Lisa
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Johnson James
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Juran David
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Lawal Mohammed
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Parish Douglas
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Trutna Tom
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Urness Todd
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


Last Name First Name Middle Name
Volk David
Street Address 1 Street Address 2
4450 Excelsior Blvd. Suite 100
City State/Province/Country ZIP/PostalCode
St. Louis Park MINNESOTA 55416
Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):


4. Industry Group

Agriculture
Banking & Financial Services
X Commercial Banking
Insurance
Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy
Health Care
Biotechnology
Health Insurance
Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate
Retailing
Restaurants
Technology
Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
Other

5. Issuer Size

Revenue Range OR Aggregate Net Asset Value Range
No Revenues No Aggregate Net Asset Value
$1 - $1,000,000 $1 - $5,000,000
$1,000,001 - $5,000,000 $5,000,001 - $25,000,000
$5,000,001 - $25,000,000 $25,000,001 - $50,000,000
$25,000,001 - $100,000,000 $50,000,001 - $100,000,000
Over $100,000,000 Over $100,000,000
X Decline to Disclose Decline to Disclose
Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)
X Rule 506(b)
Rule 506(c)
Securities Act Section 4(a)(5)
Investment Company Act Section 3(c)
Section 3(c)(1) Section 3(c)(9)
Section 3(c)(2) Section 3(c)(10)
Section 3(c)(3) Section 3(c)(11)
Section 3(c)(4) Section 3(c)(12)
Section 3(c)(5) Section 3(c)(13)
Section 3(c)(6) Section 3(c)(14)
Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2025-06-24 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?
Yes X No

9. Type(s) of Securities Offered (select all that apply)

Equity Pooled Investment Fund Interests
X Debt Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $100,000 USD

12. Sales Compensation

Recipient
Recipient CRD Number None
Piper Sandler & Co. 000000665
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
800 Nicollet Mall
City State/Province/Country ZIP/Postal Code
Minneapolis MINNESOTA 55402
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States
All States
Foreign/non-US
ILLINOIS
MINNESOTA
NEBRASKA
NEW JERSEY
OKLAHOMA

Recipient
Recipient CRD Number None
D.A. Davidson & Co. 000000199
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
227 W. Monroe Suite 5250
City State/Province/Country ZIP/Postal Code
Chicago ILLINOIS 60606
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States
All States
Foreign/non-US
ILLINOIS
MINNESOTA
NEBRASKA
NEW JERSEY
OKLAHOMA

Recipient
Recipient CRD Number None
Hovde Group LLC 000025425
(Associated) Broker or Dealer X None
(Associated) Broker or Dealer CRD Number X None
None None
Street Address 1 Street Address 2
1629 Colonial Parkway
City State/Province/Country ZIP/Postal Code
Inverness ILLINOIS 60067
State(s) of Solicitation (select all that apply)
Check "All States" or check individual States
All States
Foreign/non-US
ILLINOIS
MINNESOTA
NEBRASKA
NEW JERSEY
OKLAHOMA

13. Offering and Sales Amounts

Total Offering Amount $80,000,000 USD
or Indefinite
Total Amount Sold $80,000,000 USD
Total Remaining to be Sold $0 USD
or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
37

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions $1,000,000 USD
Estimate
Finders' Fees $0 USD
Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0 USD
Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
Bridgewater Bancshares Inc /s/ Joe Chybowski Joe Chybowski President and CFO 2025-07-08

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


FAQ

How much can BioCardia (BCDA) now raise under its updated ATM program?

The prospectus supplement authorizes up to $3,633,730 of additional common-stock sales.

What proceeds has BioCardia already received from ATM sales?

Approximately $3.1 million in gross proceeds have been raised prior to this supplement.

Why is the offering limit set at $3.63 million?

Form S-3 Instruction I.B.6 caps issuance at one-third of the $12.8 million non-affiliate float.

What is the last reported share price referenced in the filing?

The last Nasdaq closing price quoted is $2.10 per share on July 7, 2025.

Who is acting as sales agent for the ATM offering?

H.C. Wainwright & Co. serves as the exclusive sales agent or principal.

How much has BioCardia sold under I.B.6 limits in the last 12 months?

The company has sold about $0.6 million of common stock within the current 12-month period.
Bridgewater Banc

NASDAQ:BWBBP

BWBBP Rankings

BWBBP Latest News

BWBBP Latest SEC Filings

BWBBP Stock Data

2.76M
Banks - Regional
State Commercial Banks
Link
United States
ST. LOUIS PARK